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Abstract
Respiratory syncytial virus (RSV) infection remains a significant global health burden 
disproportionately affecting infants and leading to long-term lung disease. IL-17A has been shown 
to be involved in regulating viral and allergic lung inflammatory responses, which has led to a 
more recent interest in its role in RSV infection. Using a neonatal mouse model of RSV, we 
demonstrate that neonates fail to develop IL-17A responses compared to adult mice; the main 
immediate IL-17A contributor in adults were γδ T cells. Antibody neutralization of IL-17A in 
adult mice caused increased lung inflammation and airway mucus from RSV, while exogenous 
IL-17A administration to RSV-infected neonates caused decreased inflammation but no change in 
airway mucus. We also observed a lack of pro-inflammatory cytokine production (IL-1β, IL-6) 
from infected neonates. Using human cord blood mononuclear cells (CBMCs) and adult peripheral 
blood mononuclear cells (PBMCs), we compared inflammasome activation by direct retinoic acid-
inducible gene I (RIG-I) agonism; CBMCs failed to induce pro-inflammatory cytokines or 
IL-17A+ γδ T cells compared to PBMCs. Our results indicate that RSV disease severity is in part 
mediated by a lack of inflammasome activation and IL-17A production in neonates.
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Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in 
infants and young children worldwide, causing an estimated 64,000,000 cases and 160,000 
deaths each year1. Clinically, severe RSV in infants is characterized by cough (with/without 
wheezing), increased airway mucus production, and increased pulmonary inflammation2. 
Alarmingly, severe RSV infection during infancy is associated with the development of long 
term airways diseases such as asthma3, 4. Data from ours and others’ laboratories have 
demonstrated that infant humans (and neonatal rodents) respond differently to RSV 
compared to adults5–7, though the precise mechanisms underlying these immunological 
differences remain largely unknown.
IL-17A belongs to the IL-17 family of cytokines, which includes six members: IL17A-F. All 
members of this family are involved in inflammatory responses; however, only IL-17A, 
IL-17F, and IL-17E (IL-25) are produced by hematopoietic cells. Though IL-17A and 
IL-17F share 50% homology and both bind the IL-17 receptor (IL-17R), IL-17A has much 
higher affinity for IL-17R and induces stronger intracellular signaling than IL-17F8. IL-17A 
is associated with a range of inflammatory diseases including rheumatoid arthritis, multiple 
sclerosis, inflammatory bowel disease, and asthma. The role(s) of IL-17 during RSV 
infection, in infants and adults, has not yet been fully elucidated.
CD4+ T cells are regarded as the main resource of IL-17A, but CD8+ T cells, gamma delta 
(γδ) T cells, NK cells, and neutrophils are also notable IL-17A producers9. Under certain 
circumstances such as viral hepatitis or allergic airway inflammation, γδ T cells have been 
reported to be the main source of IL-17A10, 11. Additionally, IL-17 production by both γδ T 
cells and CD4+ T cells is promoted by IL-1β12 – a product of inflammasome activation 
(typically via retinoic acid-inducible gene I protein [RIG-I] recognizing dsRNA during RSV 
infection13).
Recently, it has been reported that local IL-17A levels are increased during RSV infection in 
infants14. In RSV-infected adult mice, IL-17A has been shown to play a pathogenic role15 
and a protective role16 with respect to exacerbated allergic airway responses; these 
differences are possibly due to infectious dose or viral strain. While the aforementioned 
studies have helped to gain some insight into a role for IL-17A during RSV infection, they 
utilized only adult mice. Here we seek to understand the role of IL-17A in early RSV 
infections using our neonatal mouse model of RSV.
The present study explores and compares the role(s) of IL-17A in neonatal vs. adult RSV 
infection. Compared to infected adult mice, RSV-infected neonatal mice fail to produce 
IL-17A and activated-inflammasome markers such as IL-1β and IL-6. Flow cytometric 
analyses of IL-17A producing cells confirm γδ T cells as the main source of early IL-17A, 
and modulation of IL-17A during acute RSV infection significantly alters disease outcomes. 
RIG-I-dependent activation of the inflammasome in human infant cord blood mononuclear 
cells (CBMCs) and adult peripheral blood mononuclear cells (PBMCs) revealed vastly 
attenuated cytokine production in CBMCs which may explain the lack of IL-17A during 
infant RSV infection.
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IL-17A and cytokines involved in its induction are not induced following RSV infection in 
neonatal mice
To determine the association between IL-17A and RSV infection, we infected neonatal and 
adult mice with RSV and compared cytokine levels in whole lung homogenates across a 
time-course from 0.25 to 10 days post infection (dpi) looking at IL-17A protein in the lungs 
of neonatal and adult mice infected with RSV. We observed an initial significant increase in 
IL17-A in adults as compared to neonates as early as 0.5 dpi and no significant change in 
IL17-A was observed in the neonates up to 10 dpi (data not shown). The adult response 
peaked at 1 dpi. Therefore, we chose to focus our later experiments at this optimal timepoint 
(1 dpi). RSV infection significantly increased expression of IL-17A but not IL-17F in the 
lungs of adult mice (Fig. 1A, B). Cytokines involved in the induction of IL-17A including 
IL-1β and IL-6 were also elevated in the lungs of RSV infected adult mice but not RSV 
infected neonatal mice (Fig. 1C, D) compared to uninfected controls of the same age. There 
was no change in IL-23 production in response to RSV infection; however its expression 
was increased in adult lungs compared to neonatal lungs (Fig. 1E). Furthermore, expression 
of IL-22, an IL-17-induced cytokine17, 18 was observed only in the lungs of RSV infected 
adult mice (Fig. 1F).
γδ T cells are the main source of IL-17A during early RSV infection
To determine the cellular source of IL-17A in RSV-infected mice, we analyzed all IL-17A+ 
cells in the lungs by flow cytometry using surface marker expression to attribute production 
to known IL-17-producing cell populations (i.e., γδ T cells, CD4/8 T cells, NK cells, 
neutrophils) at 1 dpi. Using the percentage of these populations making up all IL-17A+ cells 
and the intensity of IL-17A expression within that respective population (i.e., iMFI), we 
were able to deduce the source of IL-17A in RSV-infected neonatal (NR) and adult (AR) 
mice compared to sham controls (NS or AS, respectively) (Fig. 2). Most notably, adult mice 
either RSV or sham infected produced the greatest amounts of IL-17A. In adults, γδ T cells 
were the main source of IL-17A during early RSV infection (Fig. 2A,B), although 
neutrophils also produced a significant amount of IL-17A following infection (~15 fold 
induction versus ~4 fold induction). In neonates, both γδ T cells and neutrophils were the 
major sources of IL-17A; however, the IL-17A iMFI was not significantly different between 
neonatal RSV or sham infected mice. The levels of γδ T cells in the lungs increased during 
RSV infection in both adults and neonates (Fig. 2C); surprisingly, the overall levels of γδ T 
cells were significantly higher in neonates. Because γδ T cells also produce IFNγ, which is 
important in anti-viral responses, we also looked at IFNγ expressing γδ T cells. The 
percentage of IFNγ producing γδ T cells were elevated only in the lungs of RSV-infected 
adult mice (Fig. 2D,F). The percentage of activated γδ T cells followed a similar trend as 
evidenced by CD69 expression (Fig. 2E).
IL-17A reduces RSV disease severity in neonatal mice
To investigate the contribution of IL-17A to RSV induced pathogenesis, we decided to 
reverse the age-specific effect of IL-17A induction by γδ T cells by neutralizing IL-17A in 
adults and supplementing IL-17A in neonates (Fig. 3). In RSV-infected adults, IL-17A 
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neutralization resulted in increased lung viral copy number (Fig. 3A), BALF lymphocytes 
and neutrophils (Fig. 3B), and pulmonary pathology (Fig. 3C,D). Administration of 
recombinant IL-17A (rIL-17) during RSV infection in neonatal mice did not alter lung viral 
copy number (Fig. 3E), resulted in significant decreases in total BALF cellularity (Fig. 3F), 
and significantly improved lung pathology (Fig. 3G,H). None of these groups displayed 
measurable airway mucus production (data not shown).
IL-17A levels during initial RSV infection dictates pathology following RSV reinfection
We have previously demonstrated that RSV reinfection of mice initially infected as neonates 
(but, importantly, not as adults) results in substantial immunopathophysiology which closely 
mimics what is seen clinically in human infants with severe RSV6, 19. In order to observe 
the impacts of respectively decreasing or increasing IL-17A during initial RSV infection on 
reinfection responses in adults and neonates, mice treated as in Figure 3 were reinfected with 
RSV 28 days after initial infection (Fig. 4). Following reinfection, mice initially infected as 
adults and treated with IL-17A-neutralizing antibody (ARR+IL-17Ab) during the initial 
infection had significantly elevated lymphocyte and neutrophil numbers in the BALF (Fig. 
4A). Compared to controls (ARR+Control Ab), these mice exhibited significantly worse 
lung pathology with increased peribronchiolar/perivascular infiltrates (Fig. 4B) and 
increased mucus-producing cells in the airways (Fig. 4C). Following reinfection, mice 
initially infected as neonates and treated with rIL-17A (NRR+rIL-17) during the initial 
infection displayed decreased lymphocyte and neutrophil numbers in the BALF compared to 
controls (NRR+PBS) (Fig. 4D). Though lung immunopathology in both of these groups 
were expectedly worse compared to that following initial infection, the NRR+rIL-17 group 
had significantly less peribronchiolar/perivascular inflammation (Fig. 4E). Quantitatively, 
airway mucus was not affected by rIL-17 administration during initial infection in the 
neonate (Fig. 4F).
Adoptive transfer of adult γδ T cells is sufficient to protect against RSV-induced pathology 
in neonates
Our data indicated that neonatal mice have impaired γδ T cell function with respect to RSV-
induced IL-17A induction, and that in neonatal mice disease severity was reduced with 
rIL-17 treatment during initial infection. Since adult γδ T cells appeared to be more 
functionally competent, we isolated these cells from the lungs of naïve adult mice and 
adoptively transferred them intranasally into the lungs of neonatal mice prior to initial RSV 
infection (Fig. 5). Following RSV infection, γδ T cell-recipient neonates (NR+Adult γδ T 
cells) displayed significantly more IL-17A in the lungs (Fig. 5A), less total cells in the 
BALF (mainly due to decreased monocyte and neutrophil numbers) (Fig. 5B), and 
significantly decreased peribronchiolar/perivascular infiltrates (Fig. 5C,D).
Impaired IL-17A and IFNγ responses in γδ T cells following inflammasome activation in 
human cord blood mononuclear cells
Our initial cytokine data demonstrated that neonates infected with RSV failed to induce 
IL1β and IL-6. This indicated a defect in inflammasome activation during neonatal RSV 
infection. To explore this effect in vitro, we treated infant human cord blood mononuclear 
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cells (CBMCs) and adult peripheral blood mononuclear cells (PBMCs) with a RIG-I agonist 
(Fig. 6). The amount of γδ T cells remained significantly higher in adult PBMCs, 
independent of culture time or treatment (Fig. 6A). Additionally, γδ T cells in adult PBMCs 
had elevated IL-17A and IFNγ responses compared to CBMCs (Fig. 6B,C). Cytokine 
production was measured in culture supernatants; RIG-I treatment resulted in significantly 
higher production of IL-1β, IL-6, and TNFα in PBMCs but not in CBMCs (Fig. 6D–F). 
IL-18 was observed only in PBMC supernatants; no difference was observed between 
control and RIG-I agonist-treated PBMC samples (Fig. 6G). Moreover, activated caspase-1 
expression was significantly elevated in γδ T cells from adult PBMCs (Fig. 6H).
Discussion
The relatively recent research focus on infant immunity has helped to gain mechanistic 
insight as to how and why this population is immunologically distinct from adults. Severe 
RSV infection remains an important public health issue due to its prevalence in infants, 
association with long-term airway disease, and lack of effective prophylactic treatment1–3. 
Our neonatal mouse model of RSV infection recapitulates many of the symptoms observed 
in RSV-infected human infants, making it an appropriate translational tool5–7; typically, 
mice infected initially as adults fail to develop long-term airways dysfunction and do not 
develop significant pulmonary inflammation or airway mucus to the same degree as mice 
initially infected as neonates.
Though less numerous than conventional T cells, γδ T cells are critical regulators of 
inflammation and virally-exacerbated allergic disease20, 21. Here, we demonstrated that early 
(1 dpi) γδ T cell-mediated IL-17A responses are attenuated in neonates infected with RSV 
compared to adults. Surprisingly, infected neonates have significantly higher numbers of γδ 
T cells in the lung at this time point, though they are less activated. Antibody-mediated 
neutralization of IL-17A in adult mice during initial infection resulted in enhanced 
pulmonary inflammation and mucus, while treatment with rIL-17 in neonatal mice during 
initial infection resulted in an attenuation of pulmonary inflammation and airway mucus. 
These data support a protective role for IL-17A during RSV infection. Interestingly, one 
study comparing plasma cytokine levels in infants found significantly elevated IL-17A (~40 
fold) in infants with moderate RSV disease compared to those with severe RSV disease22. 
Additionally, lower IL-17A concentrations have also been observed in BALF from infant 
patients requiring ventilation for severe RSV compared to non-ventilated RSV patients14. 
Both of these clinical studies support a protective role for IL-17A during infant RSV 
infection, and indicate that varied IL-17A responses could be partly responsible for 
moderate vs. severe disease. Unfortunately, there are no comparative IL-17A data in RSV-
infected adult humans, although our mouse data suggest fully competent inflammasome 
activation and IL-17A production play a major role.
Existing studies that examine IL-17A and RSV in mice demonstrate the importance of 
IL-17A in disease outcomes. In an RSV/OVA model of allergic lung inflammation, RSV-
induced IL-17A decreased airway inflammation, eosinophilia, neutrophilia, and airway 
hyperresponsiveness16, which agrees with our own data demonstrating IL-17A as a negative 
regulator. However, another group demonstrated that IL-17A neutralization during RSV 
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infection causes decreased airway mucus and neutrophilia15. In addition to being primarily 
focused on allergic airways disease clinically associated with RSV, these studies differ from 
the present one by RSV strain used and, most importantly, in the age of the mouse at initial 
RSV infection – adults. The pathogenesis of RSV strain A2, used in the present study, has 
been directly compared to strain Line 19 and has proven to induce less morbidity with 
respect to mucus induction and airway dysfunction23, 24. Indeed, this study and our previous 
studies with strain A2 have shown mild disease upon initial infection, but greater disease 
upon reinfection which has high clinical correlativity5, 6, 25. In an IL-13-induced airway 
inflammation model, exogenous IL-17A treatment had dose-dependent effects; while a 
lower dose of IL-17A decreased γδ T cell influx but greatly increased eosinophilia, a higher 
dose of IL-17A paradoxically decreased all pulmonary inflammation26. Furthermore, this 
same study demonstrated the inflammation-inhibiting effects of IL-17A-producing γδ T cells 
adoptively transferred into naïve mice. In our study, neonatal mice infected with RSV had 
higher numbers of lung γδ T cells compared to adults, however, the IL-17A production and 
overall activation status of these cells were significantly attenuated. In humans, similar 
lymphocyte functional deficits have been demonstrated in infant populations27, 28. Despite 
the well-established role of CD8+ T cells in mediating RSV in adult mice29, 30, recent 
evidence in human infants suggests that innate immune cells (e.g., macrophages, 
neutrophils, γδ T cells) may be more important for viral clearance due to the absence of an 
efficient lymphocyte response31.
We observed a large disparity in pro-inflammatory cytokine production (i.e., IL-1β, IL-6; 
IL17A) in RSV-infected neonates compared to adults. Because IL-1β is a direct product of 
inflammasome activation and IL-17A is a product of inflammasome-activated γδ T cells, we 
hypothesized that this was due to impaired activation of the inflammasome. IL-17A is 
essential for lung inflammation caused by viral-based synthetic dsRNA32, and has been 
shown to act in vitro as a super-inducer of RSV- and RIG-I agonist-induced pro-
inflammatory responses33. We compared the ability of a known inflammasome signaling 
mediator involved in early anti-RSV responses34, 35, RIG-I, to activate the inflammasome 
and signal pro-inflammatory cytokine production in CBMCs vs. adult PBMCs. We 
unexpectedly observed a higher total number of γδ T cells in adult PBMCs, which contrasts 
what we observed in mice. We attribute this difference to measuring two different biological 
compartments (lung vs. periphery) and experimental methods (in vivo vs. in vitro) in which 
cell recruitment to the lungs may/may not take place. This effect has also been observed by 
other groups36. However, similar to the RSV-infected neonatal mice, the RIG-I agonist-
stimulated CBMCs failed to exhibit increases in IL-1β, IL-6, IL-18, and TNFα compared 
with the adult PBMCs. Additionally, RIG-I activation caused significantly elevated IL-17A 
and IFNγ responses in γδ T cells from adult PBMCs but not CBMCs. Cleavage and 
activation of caspase-1 is the hallmark of inflammasome activation37, and γδ T cells from 
CBMCs displayed a relative lack of active caspase-1 compared to that of adult PBMCs. To 
summarize, in response to RSV infection we observed that 1) there are more γδ T cells in the 
neonatal lung; 2) neonatal mice produce less IL-1β, a product of inflammasome activation, 
than adult mice; and 3) although there are more γδ T cells in the lungs of the neonate, these 
cells are less capable of producing IL-17A on a per cell basis or in bulk in response to RSV 
infection. If you combine this with our data from CBMCs demonstrating a decreased ability 
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of these cells to cleave and activate caspase-1 or to produce IL-1β, IL-18, or IL-17A 
following stimulation with RIG-I agonist, then our data cumulatively suggest that neonatal 
γδ T cells are inherently defective in inflammasome activation.
Our findings have demonstrated further differences between neonatal and adult immunity, 
and strengthened the argument that age-appropriate animal models are vital for 
understanding/ successful translation of infant disease. Admittedly, more extensive studies 
on IL-17A in human infant RSV disease are necessary to better understand its role(s), and 
whether it is a suitable target for therapy.
Methods
Mice
BALB/c mice were purchased as breeders from Harlan Laboratories (Indianapolis, IN, 
USA). All mice were housed in the vivarium at the University of Tennessee Health Science 
Center, were maintained in ventilated microisolator cages, and housed in a specific 
pathogen-free animal facility. Breeders were time mated, and age-matched 5 day old pups 
were used for neonatal experiments and 6–8 week old female mice were used for adult 
experiments. All animal protocols were prepared in accordance with the Guide for the Care 
and Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee at the University of Tennessee Health Science Center.
RSV infection
Human RSV strain A2 was purchased as a sucrose-gradient purified virus from Advanced 
Biotechnologies (Columbia, MD, USA). The virus preparation was determined to be free of 
bacteria, yeast, and fungi. For all mouse studies, the virus was propagated in Vero cells 
(ATCC; Manassas, VA, USA) using serum free medium (SFM4MegaVir™; HyClone, 
Logan, UT, USA) and stored at −80°C until use. For neonatal infections, 5 day old pups 
were anesthetized with 5% isofluorane and infected intranasally with 2×105 median tissue 
culture infective dose (TCID50) per gram of body weight in 10 μl total volume. Similarly, 
adult mice were isofluorane-anesthetized and intranasally infected with 2×105 TCID50 per 
gram of body weight in 50 μl total volume. Sham control mice were given the same volume 
of vehicle instilled intranasally. All reinfections occurred 28 days post-initial infection with 
2×105 TCID50 per gram of body weight in 50 μl total volume.
Protein detection
The levels of IL-17A and IL-1β in homogenized whole lungs were detected by ELISA 
(R&D; Minneapolis, MN, USA) according to manufacturer’s instructions. The levels of 
IL-6, IL-23a, IL-22, and IL-17F in homogenized whole lungs were detected by cytokine 
multiplex (Millipore; Billerica, MA, USA according to manufacturer’s instructions. Assay 
sensitivity for each cytokine is 5 pg/ml, 4.8 pg/ml, 7.8 pg/ml, 342 pg/ml, 2.4 pg/ml, and 10 
pg/ml, respectively. Values below the detection limit of the assay were excluded. Values 
were then plotted per mg of total lung protein.
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Lung single cell suspensions were prepared using a standardized protocol as previously 
described38. Cells were stained with the following antibodies from BD Biosciences and 
eBioscience: eFluor450-CD3 (17A2), PerCP-CD4 (RM4-5), FITC-CD8a (53-6.7), Biotin-
TCRγδ (GL3), PE-Streptavidin, APC-IL-17A (eBio17B7), APC-IFNγ (XMG1.2), FITC-
CD69 (H1.2F3), PerCP-Cy5.5-Gr1 (RB6-8C5), and PECy7-panNK (DX5). For intracellular 
staining, cells were stimulated for 5 h with 5 ng/ml PMA and 500 ng/ml ionomycin (Sigma-
Aldrich; St. Louis, MO, USA) in the presence of a protein-transport inhibitor (GolgiPlug, 
BD Biosciences; San Jose, CA, USA). Following stimulation, cells were collected, stained 
with a fixable viability dye (eBioscience), fixed, permeabilized (Fixation and 
Permeabilization Buffer; eBioscience), then intracellularly stained. Samples were read using 
a FACSCanto II (BD Biosciences) flow cytometer and analyzed with FlowJo software 
(version 7.6.5 for Windows; Tree Star; Ashland, OR, USA). To simultaneously compare 
both quantity (% of cells) and quality (intensity of staining) of IL-17-producing populations, 
integrated median fluorescent intensity (iMFI) was calculated by multiplying percent of x 
cell type (i.e., CD4, CD8, γδ, Gr1, NK) of total IL-17A+ cells multiplied by the IL-17A MFI 
of x cell type.
BALF cellularity
Bronchoalveolar lavage fluid was isolated by flushing mouse lungs with PBS containing 2% 
BSA (1.0 ml for adults and 0.1 ml for neonates). Collected cells were spun onto glass slides 
and stained with a Hema-3 staining kit (Thermo Fisher Scientific; Logan, UT, USA). 
Differential cell counts were determined by two unbiased observers in a blinded manner 
using standard morphological criteria.
Lung histopathology
Mice were euthanized and retrograde perfusion performed to remove blood from the lungs. 
The lungs were then gravity inflated with zinc formalin. Following fixation, lungs were 
paraffin embedded, sectioned, mounted on slides, and stained with either hematoxylin and 
eosin or Periodic Acid Schiff (PAS) to quantify cellular infiltrates or airway mucus 
production, respectively. Images were acquired and analyzed with the EVOS imaging 
system (Life Technologies; Carlsbad, CA, USA). Inflammation index was quantified by 
manually counting the number of peribronchiolar/perivascular inflammatory cells divided by 
the peribronchiolar/perivascular area (mm2). Mucus expression was quantified as the 
number of mucus positive cells per total circumference length of airway (mm).
Viral burden
RSV viral burden in the lungs was assessed using a well-established protocol, which has 
been shown to strongly correlate with viral load as determined by plaque assay25, 39, 40. 
Briefly, real-time PCR was performed on normalized total lung RNA as previously 
described. NS1 primers, forward: 5′-CACAACAATGCCAGTGCTACAA-3′, reverse: 5′-
TTAGACCATTAGGTTGAGAGCAATGT-3′ (IDT; Coralville, IA).
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In vivo IL-17 modulation
Neonatal mice were administered recombinant IL-17A intranasally (Peprotech; 20 ng in 10 
μl PBS 0.1% BSA) 2 hr post RSV infection and again 48 hr post RSV infection. Control 
animals were administered vehicle. Adult mice were injected i.p. with 300 μg anti-IL-17A 
antibody (Amgen; Thousand Oaks, CA, USA) 2 hr prior to RSV infection, then again 48 hr 
and 96 hr post RSV infection. Controls were administered IgG isotype control antibody 
(Southern Biotech; Birmingham, AL, USA).
Gamma delta T cell adoptive transfer
Lung single cell suspensions from adult mice were prepared using a standardized protocol as 
previously described38. Cells were centrifuged on a Ficoll-gradient to isolate mononuclear 
cells, and γδ T cells were isolated using a positive selection kit (Miltenyi Biotech; 
Germany). Cells were adoptively transferred intranasally (6.2×104 cells, based on number of 
γδ T cells in RSV-infected adult) into neonates 2 hr prior to RSV infection. Sample isolation 
purity and adoptive transfer efficiency were verified by flow cytometry.
CBMC/PBMC RIG-I activation
Purified CBMCs and PBMCs from individual donors (AllCells.com) were thawed and 
counted according to supplier’s recommendations. Cells were cultured in a 96-well, flat 
bottom plate (USA Scientific; Ocala, FL, USA) in RPMI 1640 medium containing 2 mM L-
glutamine, 1 mM sodium pyruvate, and 10% FBS (HyClone; Logan, UT, USA). 2 × 105 
total cells/well were treated with 1 μg/ml RIG-I agonist (5′ppp-dsRNA complexed with 
LyoVec; Invivogen, San Diego, CA, USA) or media control for 48 hr. For intracellular 
cytokine staining, a protein transport inhibitor was added during the final 5 hr of incubation 
(GolgiPlug; BD Bioscience, San Jose, CA, USA). Cells were stained with the following 
antibodies from eBioscience or BD Biosciences: eFluor450-CD3 (OKT3), FITC/PE-TCRγδ 
(B1.1), APC-IL-17A (8D4-8), PE-IFNγ (4S.B3). For detection of activated caspase-1, live 
cells were incubated with FAM-FLICA Caspase-1 Kit (ImmunoTechnologies; Bloomington, 
IN) during the final hour of incubation. Culture supernatants were flash frozen and stored at 
−80C° until cytokine multiplex (Millipore; Billerica, MA, USA) or ELISA (eBioscience) 
analysis according to manufacturer’s instructions; concentrations below the detection limit 
of the assay were excluded.
Statistics
Data are presented as means ± SEM using Prism5 (Graphpad; La Jolla, CA, USA). Statistics 
were analyzed with Prism5 and InStat3 (Graphpad; La Jolla, CA, USA). Two-way ANOVA 
with Bonferroni post-tests or student’s t-tests (paired or unpaired) were used to compare 
groups, where appropriate. P values <0.05 were considered significant.
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Figure 1. IL-17A and cytokines involved in its induction are not induced following RSV infection 
in neonatal mice
Neonates (5 days old) and adults (6–8 weeks old) were infected with RSV and cytokine 
protein levels in whole lung homogenates was determined at 1 dpi by ELISA (IL-17A, 
IL-1β) or multiplex assay (IL-17F, IL-6, IL-23, IL-22). Levels of IL-17A (A), IL-17F (B), 
IL-1β (C), IL-6 (D), IL-23 (E), and IL-22 (F) were normalized to pg/mg of total lung 
protein. Control mice were age-matched and sham (serum-free media) infected. Data are 
representative of at least two independent experiments. N = 4–6 mice per group per 
experiment, n/a = levels below detection. Data plotted as means ± SEM. *P<0.05 vs. age-
matched control group, #P<0.05 vs. opposite age group. Two-way ANOVA with Bonferroni 
post-test.
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Figure 2. γδ T cells are the main source of IL-17A during early RSV infection
Neonates and adults were infected with RSV and at 1 dpi lung cells were isolated. Cells 
were stimulated in vitro with PMA and ionomycin, stained with dead cell-excluding dye and 
antibodies to IL-17A, IFNγ, CD3, CD4, CD8, CD69, TCRγδ, panNK, and GR1. The cells 
were then analyzed by flow cytometry. (A) Integrated median fluorescent intensity (iMFI) of 
IL-17A for γδ T cells, CD4 T cells, CD8 T cells, NK cells, and neutrophils. (B) 
Representative flow cytometry plots demonstrating IL-17A contribution by cell population 
in RSV-infected neonates (black fill) and adults (open) compared with IL-17A FMO 
controls (grey fill). The iMFI for neonates (black fill text) and adults (black outline with 
open fill text) is shown as an inset in each histogram. (C) Levels of γδ T cells in the lungs. 
(D) Percent of γδ T cells expressing IFNγ. (E) Percent of γδ T cells expressing CD69. (F) 
Representative flow cytometry plots demonstrating IFNγ and IL-17A expression by γδ T 
cells. Control mice were age-matched and sham (serum-free media) infected. Data are 
representative of three independent experiments. N = 4–6 mice per group per experiment. 
Data plotted as means ± SEM. *P<0.05 vs. age-matched control group, #P<0.05 vs. 
opposite age group. Two-way ANOVA with Bonferroni post-test.
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Figure 3. IL-17A reduces RSV disease severity in neonatal mice
Neonates and adults were pre-treated with rIL-17 or anti-IL-17A antibody, respectively, and 
infected with RSV. At 4 dpi, pulmonary RSV levels, BALF cellularity, or lung 
histopathology were determined. (A, E) Pulmonary RSV levels determined by fold 
expression of NS1 mRNA in adults and neonates, respectively. (B, F) Total BALF counts 
and differentials from treated and infected adults and neonates, respectively. (C, G) 
Inflammatory index of lung histopathology from treated and infected adults and neonates, 
respectively. (D, H) Representative 20x images of H&E stained lung sections showing 
peribronchiolar/perivascular inflammation. The arrowheads indicate cellular infiltrates. Data 
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are representative of at least two independent experiments. N=4–6 mice per group per 
experiment. Data plotted as means ± SEM. *P<0.05 vs. control groups. Student’s t-test.
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Figure 4. IL-17A levels during initial RSV infection dictates pathology following RSV reinfection
Neonates and adults were infected and reinfected with RSV at 4 weeks postprimary 
infection. BALF cellularity and lung histopathology were determined at 6 days 
postsecondary infection. (A, D) Total BALF counts and differentials from reinfected mice 
that were initially treated and infected as adults or neonates, respectively. (B, E) 
Inflammatory index and representative 20x images of H&E stained lung sections showing 
peribronchiolar/perivascular inflammation. The arrowheads indicate cellular infiltrates. (C, 
F) Mucus index and representative 40x images of airway epithelium. Data are representative 
of at least two independent experiments. N=4–6 mice per group per experiment. Data plotted 
as means ± SEM. *P<0.05 vs. control groups. Student’s t-test.
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Figure 5. Adoptive transfer of adult γδ T cells is sufficient to protect against RSV-induced 
pathology in neonates
γδ T cells from adults were adoptively transferred into the lungs of neonates prior to RSV 
infection. (A) Whole lung IL-17A levels from RSV-infected neonatal mice pre-treated with 
adult γδ T cells or vehicle control, determined at 1 dpi. (B) Total BALF counts and 
differentials determined at 4dpi. (C, D) Inflammatory index and representative 20x (top) 
images with enhanced 60x inset (bottom) images of H&E stained lung sections showing 
peribronchiolar/perivascular inflammation. Data are representative of at least two 
independent experiments. N=5 mice per group per experiment. Data plotted as means ± 
SEM. *P<0.05 vs. control groups. Student’s t-test.
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Figure 6. Impaired IL-17A and IFNγ responses in γδ T cells following inflammasome activation 
in human cord blood mononuclear cells
Human CBMCs and adult PBMCs (2 × 105 cells/well) were treated in vitro with a RIG-I 
agonist (1 μg/ml, 48 hr). (A) γδ T cells were quantified in pre- and post-treatment samples 
by flow cytometry. (B,C) Following incubation, IL-17A and IFNγ iMFI was determined in 
γδ T cells by flow cytometry. Production of IL-1β (D), IL-6 (E), TNFα (F), and IL-18 (G) 
were measured in cell culture supernatants by multiplex or ELISA assay. (H) Expression of 
active caspase-1in CBMCs (black fill) vs. adult PBMCs (open) compared to FMO control 
(grey fill). Data are representative of four independent experiments. N=5 samples per group 
from individual donors per experiment. Data plotted as means ± SEM. *P<0.05 vs. control 
groups. Paired student’s t-test.
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